Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the vascular damage that triggers progression to shock, and using a companion diagnostic to identify patients most likely to get to that point.

Adrenomed AG’s first-in-class antibody, which binds the biologically active form of the peptide hormone adrenomedullin (ADM), is designed to prevent progression from sepsis to septic shock...